| 臺大學術典藏 |
2020-09-23T06:22:32Z |
The Association of Infrared Imaging Findings of the Breast with Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Status of Breast Cancer
|
Wang J.;Shih T.T.F.;Ruoh-Fang Yen;Lu Y.-S.;Chen C.-Y.;Mao T.-L.;Lin C.-H.;Kuo W.-H.;Tsai Y.-S.;Chang K.-J.;Chien K.-L.; Wang J.; Shih T.T.F.; RUOH-FANG YEN; Lu Y.-S.; Chen C.-Y.; Mao T.-L.; Lin C.-H.; Kuo W.-H.; Tsai Y.-S.; Chang K.-J.; Chien K.-L. |
| 臺大學術典藏 |
2020-09-22T07:39:51Z |
A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer
|
Cheng A.-L.; Shih T.T.-F.; Wei S.-Y.; Yu C.-W.; CHAO-YU HSU; Wu P.-F.; Chen W.-W.; Lin C.-H.; Lu Y.-S.; Chen B.-B. |
| 臺大學術典藏 |
2020-08-14T08:39:03Z |
Evaluation of the treatment response to neoadjuvant chemotherapy in locally advanced breast cancer using combined magnetic resonance vascular maps and apparent diffusion coefficient
|
Lu Y.-S.; Chen H.-H.; JO-YU CHEN; Chang Y.-C.; Huang C.-S.; Chang R.-F.; Wu L.-A. |
| 臺大學術典藏 |
2020-08-14T03:15:35Z |
Pneumatosis coli after etoposide chemotherapy for breast cancer
|
Liu K.-L.; Wang H.-P.; Lu Y.-S.; I-LUN SHIH; I-Lun Shih;Lu Y.-S.;Wang H.-P.;Liu K.-L. |
| 臺大學術典藏 |
2020-08-13T06:33:46Z |
Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas
|
Lin C.-H.; Cheng A.-L.; Wu S.-G.; JIN-YUAN SHIH; Wu P.-F.; Huang W.-C.; Yang J.C.-H.; Lu Y.-S. |
| 臺大學術典藏 |
2020-08-12T02:42:38Z |
Imaging biomarkers from multiparametric magnetic resonance imaging are associated with survival outcomes in patients with brain metastases from breast cancer
|
Bang-Bin Chen;Lu Y.-S.;Yu C.-W.;Lin C.-H.;Chen T.W.-W.;Wei S.-Y.;Cheng A.-L.;Shih T.T.-F.; BANG-BIN CHEN; Lu Y.-S.; Yu C.-W.; Lin C.-H.; Chen T.W.-W.; Wei S.-Y.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2020-08-06T07:51:58Z |
The Association of Infrared Imaging Findings of the Breast with Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Status of Breast Cancer
|
Chien K.-L.; Wang J.; TIFFANY TING-FANG SHIH; Yen R.-F.; Lu Y.-S.; Chen C.-Y.; Mao T.-L.; Lin C.-H.; Kuo W.-H.; Tsai Y.-S.; Chang K.-J. |
| 臺大學術典藏 |
2020-08-06T07:51:48Z |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Lu Y.-S.;Chen T.W.-W.;Lin C.-H.;Yeh D.-C.;Tseng L.-M.;Wu P.-F.;Rau K.-M.;Chen B.-B.;Chao T.-C.;Huang S.-M.;Huang C.-S.;Tiffany Ting-Fang Shih;Cheng A.-L.;Taiwan Breast Cancer Consortium; Lu Y.-S.; Chen T.W.-W.; Lin C.-H.; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Rau K.-M.; Chen B.-B.; Chao T.-C.; Huang S.-M.; Huang C.-S.; TIFFANY TING-FANG SHIH; Cheng A.-L.; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2020-08-06T07:51:46Z |
A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer
|
Lu Y.-S.; Lin C.-H.; Chen W.-W.; Wu P.-F.; Hsu C.-Y.; Yu C.-W.; Wei S.-Y.; Cheng A.-L.; TIFFANY TING-FANG SHIH; Chen B.-B. |
| 臺大學術典藏 |
2020-08-06T07:51:43Z |
Imaging biomarkers from multiparametric magnetic resonance imaging are associated with survival outcomes in patients with brain metastases from breast cancer
|
TIFFANY TING-FANG SHIH; Chen B.-B.;Lu Y.-S.;Yu C.-W.;Lin C.-H.;Chen T.W.-W.;Wei S.-Y.;Cheng A.-L.;Tiffany Ting-Fang Shih; Chen B.-B.; Lu Y.-S.; Yu C.-W.; Lin C.-H.; Chen T.W.-W.; Wei S.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2020-07-09T02:57:01Z |
A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer
|
Chen B.-B.;Lu Y.-S.;Lin C.-H.;Chen W.-W.;Wu P.-F.;Hsu C.-Y.;Chih-Wei Yu;Wei S.-Y.;Cheng A.-L.;Shih T.T.-F.; Chen B.-B.; Lu Y.-S.; Lin C.-H.; Chen W.-W.; Wu P.-F.; Hsu C.-Y.; CHIH-WEI YU; Wei S.-Y.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2020-07-09T02:57:00Z |
Imaging biomarkers from multiparametric magnetic resonance imaging are associated with survival outcomes in patients with brain metastases from breast cancer
|
Chen B.-B.;Lu Y.-S.;Chih-Wei Yu;Lin C.-H.;Chen T.W.-W.;Wei S.-Y.;Cheng A.-L.;Shih T.T.-F.; Chen B.-B.; Lu Y.-S.; CHIH-WEI YU; Lin C.-H.; Chen T.W.-W.; Wei S.-Y.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2020-07-03T08:45:47Z |
I�eB kinases increase Myc protein stability and enhance progression of breast cancer cells
|
Yeh P.-Y ;Lu Y.-S ;Da-Liang Ou ;Cheng A.-L.; Yeh P.-Y; Lu Y.-S; DA-LIANG OU; Cheng A.-L. |
| 臺大學術典藏 |
2020-07-03T08:28:22Z |
The detection and identification of saliva in forensic samples by RT-LAMP
|
Linacre A.; Hsieh H.-M.; Tsai L.-C.;Su C.-W.;James Chun-I Lee;Lu Y.-S.;Chen H.-C.;Lin Y.-C.;Linacre A.;Hsieh H.-M.; Tsai L.-C.; Su C.-W.; JAMES CHUN-I LEE; Lu Y.-S.; Chen H.-C.; Lin Y.-C. |
| 臺大學術典藏 |
2020-05-26T09:27:31Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Hsu C.-H;Cheng A.-L;Hsu C;Chih-Hsin Yang;Lu Y.-S;Lin C.-C;Bu C.-F;Yeh K.-H.; Hsu C.-H; Cheng A.-L; Hsu C; CHIH-HSIN YANG; Lu Y.-S; Lin C.-C; Bu C.-F; Yeh K.-H. |
| 臺大學術典藏 |
2020-05-26T09:27:29Z |
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract
|
Hsu C;Shen Y.-C;Chih-Hsin Yang;Yeh K.-H;Lu Y.-S;Hsu C.-H;Liu H.-T;Li C.-C;Chen J.-S;Wu C.-Y;Cheng A.-L.; Hsu C; Shen Y.-C; CHIH-HSIN YANG; Yeh K.-H; Lu Y.-S; Hsu C.-H; Liu H.-T; Li C.-C; Chen J.-S; Wu C.-Y; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-26T09:27:29Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Lu Y.-S;Hsu C;Li C.-C;Kuo S.-H;Yeh K.-H;Chih-Hsin Yang;Hsu C.-H;Wu C.-Y;Cheng A.-L.; Lu Y.-S; Hsu C; Li C.-C; Kuo S.-H; Yeh K.-H; CHIH-HSIN YANG; Hsu C.-H; Wu C.-Y; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-26T09:27:28Z |
Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer
|
Yeh K.H;Lu Y.S;Hsu C.H;Lin J.F;Chao H.J;Huang T.C;Chung C.Y;Chang C.S;Chih-Hsin Yang;Cheng A.L.; Yeh K.H; Lu Y.S; Hsu C.H; Lin J.F; Chao H.J; Huang T.C; Chung C.Y; Chang C.S; CHIH-HSIN YANG; Cheng A.L. |
| 臺大學術典藏 |
2020-05-26T09:27:25Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Lin C.-C;Cheng A.-L;Hsu C.-H;Lu Y.-S;Hsu C;Yeh K.-H;Wu C.-Y;Huang C.-S;Chih-Hsin Yang; Lin C.-C; Cheng A.-L; Hsu C.-H; Lu Y.-S; Hsu C; Yeh K.-H; Wu C.-Y; Huang C.-S; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:16Z |
O6-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers
|
Wu P.-F;Kuo K.-T;Kuo L.-T;Lin Y.-T;Lee W.-C;Lu Y.-S;Chih-Hsin Yang;Wu R.-M;Tu Y.-K;Tasi J.-C;Tseng H.-M;Tseng S.-H;Cheng A.-L;Lin C.-H.; Wu P.-F; Kuo K.-T; Kuo L.-T; Lin Y.-T; Lee W.-C; Lu Y.-S; CHIH-HSIN YANG; Wu R.-M; Tu Y.-K; Tasi J.-C; Tseng H.-M; Tseng S.-H; Cheng A.-L; Lin C.-H. |
| 臺大學術典藏 |
2020-05-26T09:26:57Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C;Su W.-C;Yen C.-J;Hsu C.-H;Su W.-P;Yeh K.-H;Lu Y.-S;Cheng A.-L;Huang D.C.-L;Fritsch H;Voss F;Taube T;Chih-Hsin Yang; Lin C.-C; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; Lu Y.-S; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:54Z |
High prevalence of the BIM deletion polymorphism in young female breast cancer in an East Asian country
|
Chen I.-C; Wu P.-F; Kuo S.-H; Chen C.-J; Lu Y.-S; Cheng A.-L.; Cheng A.-L.;Lu Y.-S;Chen C.-J;Kuo S.-H;Wu P.-F;Chen I.-C;Chen W.-W;Kuo K.-T;Hsiung C.-N;Chang D.-Y;Kuo W.-H;Chih-Hsin Yang;Huang C.-S;Lee J.-H;Shen C.-Y;Lin C.-H; Lin C.-H; Shen C.-Y; Lee J.-H; Huang C.-S; CHIH-HSIN YANG; Kuo W.-H; Chang D.-Y; Hsiung C.-N; Kuo K.-T; Chen W.-W |
| 臺大學術典藏 |
2020-05-25T07:35:36Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Cheng A.-L; Hsu C; Yang C.-H; Lu Y.-S; Chia-Chi Lin; Bu C.-F; Yeh K.-H.; Hsu C.-H |
| 臺大學術典藏 |
2020-05-25T07:35:34Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Chia-Chi Lin; Cheng A.-L; Hsu C.-H; Lu Y.-S; Hsu C; Yeh K.-H; Wu C.-Y; Huang C.-S; Yang C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:22Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Chia-Chi Lin; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; Lu Y.-S; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; Yang J.C.-H. |
| 臺大學術典藏 |
2020-04-28T07:25:38Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Chih-Hung Hsu;Cheng A.-L.;Hsu C.;Yang C.-H.;Lu Y.-S.;Lin C.-C.;Bu C.-F.;Yeh K.-H.; CHIH-HUNG HSU; Cheng A.-L.; Hsu C.; Yang C.-H.; Lu Y.-S.; Lin C.-C.; Bu C.-F.; Yeh K.-H. |
| 臺大學術典藏 |
2020-04-28T07:25:37Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
CHIH-HUNG HSU; Wu C.-Y.; Cheng A.-L.; Lu Y.-S.;Hsu C.;Li C.-C.;Kuo S.-H.;Yeh K.-H.;Yang C.-H.;Chih-Hung Hsu;Wu C.-Y.;Cheng A.-L.; Lu Y.-S.; Hsu C.; Li C.-C.; Kuo S.-H.; Yeh K.-H.; Yang C.-H. |
| 臺大學術典藏 |
2020-04-28T07:25:35Z |
Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer
|
Yeh K.-H.;Lu Y.-S.;Chih-Hung Hsu;Lin J.-F.;Hsu C.;Kuo S.-H.;Li Jr. S.;Cheng A.-L.; Yeh K.-H.; Lu Y.-S.; CHIH-HUNG HSU; Lin J.-F.; Hsu C.; Kuo S.-H.; Li Jr. S.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:27Z |
Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma
|
Chiang C.-T.;Yeh P.-Y.;Gao M.;Chen C.-W.;Yeh L.-C.;Feng W.-C.;Kuo S.-H.;Chih-Hung Hsu;Lu Y.-S.;Cheng A.-L.; Chiang C.-T.; Yeh P.-Y.; Gao M.; Chen C.-W.; Yeh L.-C.; Feng W.-C.; Kuo S.-H.; CHIH-HUNG HSU; Lu Y.-S.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:26Z |
Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001
|
Kuo S.-H.; CHIH-HUNG HSU; Chen L.-T.; Lu Y.-S.; Lin C.-H.; Yeh P.-Y.; Jeng H.-J.; Gao M.; Yeh K.-H.; Cheng A.-L.; Kuo S.-H. ;Chih-Hung Hsu ;Chen L.-T. ;Lu Y.-S. ;Lin C.-H. ;Yeh P.-Y. ;Jeng H.-J. ;Gao M. ;Yeh K.-H. ;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:19Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C.;Su W.-C.;Yen C.-J.;Chih-Hung Hsu;Su W.-P.;Yeh K.-H.;Lu Y.-S.;Cheng A.-L.;Huang D.C.-L.;Fritsch H.;Voss F.;Taube T.;Yang J.C.-H.; Lin C.-C.; Su W.-C.; Yen C.-J.; CHIH-HUNG HSU; Su W.-P.; Yeh K.-H.; Lu Y.-S.; Cheng A.-L.; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-04-10T12:51:30Z |
Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma
|
Chiun Hsu;Huang C.-S.;Chao T.-Y.;Lu Y.-S.;Bu C.-F.;Chen M.M.;Chang K.-J.;Cheng A.-L.; Chiun Hsu; Huang C.-S.; Chao T.-Y.; Lu Y.-S.; Bu C.-F.; Chen M.M.; Chang K.-J.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:29Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Li C.-C.; Kuo S.-H.; Yeh K.-H.; Yang C.-H.; Hsu C.-H.; Wu C.-Y.; Cheng A.-L.; Lu Y.-S.;Chiun Hsu;Li C.-C.;Kuo S.-H.;Yeh K.-H.;Yang C.-H.;Hsu C.-H.;Wu C.-Y.;Cheng A.-L.; Lu Y.-S.; Chiun Hsu |
| 臺大學術典藏 |
2020-04-10T12:51:26Z |
Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer
|
Ch'Ang H.-J.;Wang C.-C.;Cheng A.-L.;Chiun Hsu;Lu Y.-S.;Chang M.-C.;Lin J.-T.;Wang H.-P.;Shiah H.-S.;Liu T.-W.;Chang J.-Y.;Whang-Peng J.;Chen L.-T.; Ch'ang H.-J.; Wang C.-C.; Cheng A.-L.; Chiun Hsu; Lu Y.-S.; Chang M.-C.; Lin J.-T.; Wang H.-P.; Shiah H.-S.; Liu T.-W.; Chang J.-Y.; Whang-Peng J.; Chen L.-T. |
| 臺大學術典藏 |
2020-04-10T12:51:21Z |
Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma
|
Ou D.-L.; Shen Y.-C.; Liang J.-D.; Liou J.-Y.; Yu S.-L.; Fan H.-H.; Wang D.-S.; Lu Y.-S.; Chiun Hsu; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:21Z |
Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway
|
Chen K.-F.; Yeh P.-Y.; Chiun Hsu; Hsu C.-H.; Lu Y.-S.; Hsieh H.-P.; Chen P.-J.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:15Z |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma
|
Cheng A.-L.; Hsu C.-H.; Lin Z.-Z.; Chiun Hsu; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Shao Y.-Y. |
| 臺大學術典藏 |
2020-04-10T12:51:13Z |
The first two lines of chemotherapy for anthracycline-naive metastatic breast cancer: A comparative study of the efficacy of anthracyclines and non-anthracyclines
|
Chen W.-W.; Chang D.-Y.; Huang S.-M.; Lin C.-H.; Chiun Hsu; Lin M.-H.; Huang C.-S.; Lu Y.-S.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:13Z |
Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy
|
Kuo Y.-H.; Lin C.-H.; Shau W.-Y.; Chen T.-J.; Yang S.-H.; Huang S.-M.; Chiun Hsu; Lu Y.-S.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:13Z |
Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin
|
YU-YUN SHAO; Kuo K.-T.; Hu F.-C.; Lu Y.-S.; Huang C.-S.; Liau J.-Y.; Lee W.-C.; Hsu C.; Kuo W.-H.; Chang K.-J.; Lin C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:12Z |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma
|
YU-YUN SHAO; Lin Z.-Z.; Hsu C.; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:15:56Z |
Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy using LC-MS/MS
|
Lu Y.-S.; Lin C.-H.; Tsai I.-L.; Kuo C.-H.; YU-YUN SHAO; Chiu H.-H.;Liao H.-W.;Yu-Yun Shao;Lu Y.-S.;Lin C.-H.;Tsai I.-L.;Kuo C.-H.; Chiu H.-H.; Liao H.-W. |
| 臺大學術典藏 |
2020-03-27T02:23:27Z |
O6-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers
|
Lin C.-H.; Cheng A.-L.; Tseng S.-H.; Tseng H.-M.; Wu P.-F.;Kuo K.-T.;Lu-Ting Kuo;Lin Y.-T.;Lee W.-C.;Lu Y.-S.;Yang C.-H.;Wu R.-M.;Tu Y.-K.;Tasi J.-C.;Tseng H.-M.;Tseng S.-H.;Cheng A.-L.;Lin C.-H.; Wu P.-F.; Kuo K.-T.; LU-TING KUO; Lin Y.-T.; Lee W.-C.; Lu Y.-S.; Yang C.-H.; Wu R.-M.; Tu Y.-K.; Tasi J.-C. |
| 臺大學術典藏 |
2020-03-27T02:03:49Z |
Pneumatosis coli after etoposide chemotherapy for breast cancer
|
Lu Y.-S.; Shih I.-L.; Shih I.-L.;Lu Y.-S.;Wang H.-P.;Kao-Lang Liu; Wang H.-P.; KAO-LANG LIU |
| 臺大學術典藏 |
2020-03-24T04:02:56Z |
The Association of Infrared Imaging Findings of the Breast with Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Status of Breast Cancer
|
Wang J. ;Shih T.T.F. ;Yen R.-F. ;Lu Y.-S. ;Chen C.-Y. ;Mao T.-L. ;Lin C.-H. ;Wen-Hung Kuo ;Tsai Y.-S. ;Chang K.-J. ;Chien K.-L.; Wang J.; Shih T.T.F.; Yen R.-F.; Lu Y.-S.; Chen C.-Y.; Mao T.-L.; Lin C.-H.; WEN-HUNG KUO; Tsai Y.-S.; Chang K.-J.; Chien K.-L. |
| 臺大學術典藏 |
2020-03-24T04:02:55Z |
Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era
|
Lin C.H.; Chen I.C.; Chen I.C. ;Lin C.H. ;Huang C.S. ;Lien H.C. ;Hsu C. ;Wen-Hung Kuo ;Lu Y.S. ;Cheng A.L.; Huang C.S.; Lien H.C.; Hsu C.; WEN-HUNG KUO; Lu Y.S.; Cheng A.L. |
| 臺大學術典藏 |
2020-03-24T04:02:54Z |
Multimodel assessment of BRCA1 mutations in Taiwanese (ethnic Chinese) women with early-onset, bilateral or familial breast cancer
|
Cheng A.-L.; Lin C.-H.; Sargeant A.M.; Lu Y.-S.; Bai L.-Y.; Liu T.-P.; WEN-HUNG KUO; Lin P.-H.; Huang A.-C.; Chien Y.-H.; Hsieh F.-J.; Hwu W.-L.; Chang K.-J. |
| 臺大學術典藏 |
2020-03-24T04:02:47Z |
Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer
|
Wang M.-Y.; Kuo S.-H.; Lin C.-H.; Lu Y.-S.; WEN-HUNG KUO; Huang A.-C.; Lin P.-H.; Liu C.-Y.; Cheng F.T.-F.; Yeh M.-H.; Li H.-Y.; Yang Y.-H.; Hsu Y.-H.; Fan S.-C.; Li L.-Y.; Yu S.-L.; Chang K.-J.; Chen P.-L.; Ni Y.-H.; Huang C.-S. |
| 臺大學術典藏 |
2020-03-24T04:02:47Z |
TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays
|
Cheng A.-L.; Lu Y.-S.; Chen W.-W.; Chang C.-H.; Wang M.-Y.; Chang D.-Y.; Wu P.-F.; Wang C.-C.; Kuo K.-T.; WEN-HUNG KUO; Hu F.-C.; Huang C.-S.; Chen I.-C.; Lin C.-H. |
| 臺大學術典藏 |
2020-03-24T04:02:47Z |
High prevalence of the BIM deletion polymorphism in young female breast cancer in an East Asian country
|
Lu Y.-S.; Cheng A.-L.; Chen C.-J.; Kuo S.-H.; Wu P.-F.; Chen I.-C.; Chen W.-W.; Lin C.-H.; Shen C.-Y.; Lee J.-H.; Huang C.-S.; Yang C.-H.; WEN-HUNG KUO; Chang D.-Y.; Hsiung C.-N.; Kuo K.-T. |
